Matthias Bodenstedt
Chief Financial Officer
Welcome, everyone. Good morning, good afternoon. Thank you for joining today’s webcast. My name is Matthias Bodenstedt, I’m the Chief Financial Officer of MoonLake Immunotherapeutics. As usual, I’m joined here by our Co-Founder and CSO, Kristian Reich; our Co-Founder and CEO, Jorge da Silva. We are also honored to be joined today by Professor Alexa Kimball, a leading [indiscernible] in HS. We will go through the data and then look forward to the thoughts and reflections of Professor Kimball on the VELA data that we will be presenting today. In the end of the session, as usual, we will open up for Q&A.
Please take note of our disclaimer on the forward-looking statements. [Operator Instructions]. The presentation document and the replay of this presentation will be made available on our IR website on moonlaketx.com. With that, I’m handing over to Jorge.
Jorge da Silva
Co-Founder, CEO & Director
Thank you, Matthias. Also from my side, welcome all. Good morning, good afternoon, depending on where you are. Thank you for making the time to join our presentation today.
I’ll start very briefly with a quick summary of the points that we’re going to be hitting in the call today, most of which obviously has been covered in the press release that was sent out yesterday.
The main messages are that obviously, the VELA-1 and VELA-2 trials formed the VELA program, which, as you know, has been testing sonelokimab in adults with moderate to severe HS to a primary endpoint readout at week 16. Importantly, from a regulatory perspective, and obviously, for all of us, the
#MoonLake #Immunotherapeutics #Special #Call